Blood filtering for NMOSD attacks
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a blood filtering procedure called Protein A immunoadsorption for people having an acute episode of neuromyelitis optica spectrum disorder (NMOSD). It may help remove harmful antibodies from your blood and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with NMOSD and are currently having an acute attack
- You are between 18 and 65 years old
- You have tested positive for AQP4 antibodies using a special blood test
- You are not pregnant or breastfeeding
- You have not used certain immune treatments (like monoclonal antibodies) in the last 3 to 6 months
- You do not have severe bleeding problems, heart failure, or active serious infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called JYP0061 for people with NMOSD who are currently experiencing a sudden worsening of symptoms (acute attack). It aims to see if the drug can help control the attack and improve outcomes.
This study looks at patients with neuromyelitis optica spectrum disorder (NMOSD)—a rare condition affecting the nervous system—who are doing well on rituximab treatment. Researchers want to understand hidden signs of disease activity that might predict future problems, even when patients feel stable.
This trial tests a new treatment called NouvSoma001 for neuromyelitis optica spectrum disorder (NMOSD), a condition where the immune system attacks the optic nerves and spinal cord. It looks at whether the drug is safe and helps people who have had a recent attack with severe pain, trouble walking, or bladder/bowel problems.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
This study tests whether a new experimental medicine called CC-97540 is safe and well-tolerated in patients with a rare neurological disease called neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody marker (anti-AQP4). The trial involves a procedure that removes and reprocesses some of your immune cells.
Hear when a new Neuromyelitis Optica Spectrum Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.